# Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

> **NCT06300580** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 11 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ABBV-932

## Key facts

- **NCT ID:** NCT06300580
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-21
- **Primary completion:** 2025-05-26
- **Final completion:** 2025-05-26
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300580, "Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06300580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*